WO2012015910A3 - Use of adnf polypeptides for treating neurodegenerative diseases - Google Patents

Use of adnf polypeptides for treating neurodegenerative diseases Download PDF

Info

Publication number
WO2012015910A3
WO2012015910A3 PCT/US2011/045522 US2011045522W WO2012015910A3 WO 2012015910 A3 WO2012015910 A3 WO 2012015910A3 US 2011045522 W US2011045522 W US 2011045522W WO 2012015910 A3 WO2012015910 A3 WO 2012015910A3
Authority
WO
WIPO (PCT)
Prior art keywords
adnf
neurodegenerative diseases
amino acid
polypeptides
adnf polypeptides
Prior art date
Application number
PCT/US2011/045522
Other languages
French (fr)
Other versions
WO2012015910A2 (en
Inventor
Alistair James Stewart
Bruce Hisashi Morimoto
Original Assignee
Allon Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allon Therapeutics Inc. filed Critical Allon Therapeutics Inc.
Publication of WO2012015910A2 publication Critical patent/WO2012015910A2/en
Publication of WO2012015910A3 publication Critical patent/WO2012015910A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

This invention relates to the use of ADNF polypeptides in the treatment of neurodegenerative diseases based upon the identification of certain therapeutically effective pharmacokinetic parameters, dosing levels and formulations. The ADNF polypeptides include ADNF I and ADNF III (also referred to as ADNP) polypeptides, analogs, subsequences such as NAP and SAL, and D-amino acid versions (either wholly D-amino acid peptides or mixed D- and L-amino acid peptides), and combinations thereof which contain their respective active core sites.
PCT/US2011/045522 2010-07-28 2011-07-27 Use of adnf polypeptides for treating neurodegenerative diseases WO2012015910A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36848910P 2010-07-28 2010-07-28
US61/368,489 2010-07-28

Publications (2)

Publication Number Publication Date
WO2012015910A2 WO2012015910A2 (en) 2012-02-02
WO2012015910A3 true WO2012015910A3 (en) 2015-07-09

Family

ID=44629716

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/045522 WO2012015910A2 (en) 2010-07-28 2011-07-27 Use of adnf polypeptides for treating neurodegenerative diseases

Country Status (1)

Country Link
WO (1) WO2012015910A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI752907B (en) * 2015-05-08 2022-01-21 美商拜奧馬林製藥公司 Tpp1 formulations and methods for treating cln2 disease
CN112063656A (en) * 2020-08-28 2020-12-11 中国科学院广州生物医药与健康研究院 Use of Map2k3 or Map2k6 for improving efficiency of inducing adult cells to generate pluripotent stem cells

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040048801A1 (en) * 2000-05-31 2004-03-11 Spong Catherine Y Use of activity-dependent neurotrophic factor-derived polypeptides for enhancing learning and memory:pre-and post-natal administration
US20050054837A1 (en) * 2001-09-12 2005-03-10 Brenneman Douglas E. Neurothrophic componentss of the adnf 1 complex
US20070185035A1 (en) * 2005-12-23 2007-08-09 Nastech Pharmaceutical Company Inc. Enhanced mucosal administration of neuroprotective peptides
WO2009026687A1 (en) * 2007-08-24 2009-03-05 Ramot At Tel-Aviv University Ltd. Neuroprotection using nap-like and sal-like peptide mimetics
WO2010075635A1 (en) * 2008-12-30 2010-07-08 Ramot At Tel Aviv University Ltd. Combination therapies using nap

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740497A (en) 1971-06-29 1973-06-19 G Daniell Artificial line bridge subscriber dial long line equipment tester
JP3285862B2 (en) 1991-04-22 2002-05-27 アメリカ合衆国 Activity-dependent neurotrophic factor
US6174862B1 (en) 1991-04-22 2001-01-16 Ramot University Authority For Applied Research And Industrial Development, Ltd. Neurotrophic peptides of activity dependent neurotrophic factor
CA2202496C (en) 1994-10-17 2010-01-05 Douglas E. Brenneman Neurotrophic peptides of activity dependent neurotrophic factor
US6613740B1 (en) 1997-02-07 2003-09-02 Ramot University Authority For Applied Research And Industrial Development Ltd. Activity dependent neurotrophic factor III (ADNF III)
US6933277B2 (en) 1999-03-12 2005-08-23 The United States Of America As Represented By The Department Of Health And Human Services Prevention of fetal alcohol syndrome and neuronal cell death with ADNF polypeptides
US6649411B2 (en) 1999-07-30 2003-11-18 The United States Of America As Represented By The Department Of Health And Human Services Methods of inhibiting cancer cells with ADNF III antisense oligonucleotides
WO2001012654A2 (en) 1999-08-18 2001-02-22 Ramot University Authority For Applied Research & Industrial Development Ltd. Orally active peptides that prevent cell damage and death
US7960334B2 (en) 2003-03-12 2011-06-14 Ramot At Tel-Aviv University Ltd. Use of ADNF III polypeptides for treating mental diseases and disorders, including schizophrenia

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040048801A1 (en) * 2000-05-31 2004-03-11 Spong Catherine Y Use of activity-dependent neurotrophic factor-derived polypeptides for enhancing learning and memory:pre-and post-natal administration
US20050054837A1 (en) * 2001-09-12 2005-03-10 Brenneman Douglas E. Neurothrophic componentss of the adnf 1 complex
US20070185035A1 (en) * 2005-12-23 2007-08-09 Nastech Pharmaceutical Company Inc. Enhanced mucosal administration of neuroprotective peptides
WO2009026687A1 (en) * 2007-08-24 2009-03-05 Ramot At Tel-Aviv University Ltd. Neuroprotection using nap-like and sal-like peptide mimetics
WO2010075635A1 (en) * 2008-12-30 2010-07-08 Ramot At Tel Aviv University Ltd. Combination therapies using nap

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GEERTS HUGO: "AL-108 and AL-208, formulations of the neuroprotective NAP fragment of activity-dependent neuroprotective protein, for cognitive disorders.", CURRENT OPINION IN INVESTIGATIONAL DRUGS (LONDON, ENGLAND : 2000) JUL 2008 LNKD- PUBMED:18600585, vol. 9, no. 7, July 2008 (2008-07-01), pages 800 - 811, XP009153937, ISSN: 1472-4472 *
GOZES ILLANA ET AL: "Addressing Alzheimer's Disease Tangles: From NAP to AL-108", CURRENT ALZHEIMER RESEARCH, vol. 6, no. 5, October 2009 (2009-10-01), pages 455 - 460, XP009153932, ISSN: 1567-2050 *
JAVITT ET AL: "EFFECTS OF INTRANASAL AL-108 (DAVUNETIDE) ON NEUROCOGNITION AND FUNCTIONAL OUTCOME IN SCHIZOPHERENIA", SCHIZOPHRENIA RESEARCH, ELSEVIER, NETHERLANDS, vol. 117, no. 2-3, 1 April 2010 (2010-04-01), pages 118 - 119, XP026979447, ISSN: 0920-9964, [retrieved on 20100320], DOI: 10.1016/J.SCHRES.2010.02.052 *

Also Published As

Publication number Publication date
WO2012015910A2 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
NZ630536A (en) Therapeutic agent or prophylactic agent for dementia
WO2007006307A3 (en) Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
EA201201446A1 (en) PEPTIDE DERIVATIVES, THEIR PRODUCTION AND APPLICATION
MX360208B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX363136B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX360211B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
IN2012DN01584A (en)
EA201070548A1 (en) DERIVATIVES OF KERATIN AND WAYS OF THEIR OBTAINING
WO2014165607A3 (en) Aromatic-cationic peptide formulations, compositions and methods of use
UA100127C2 (en) Peptide cdh3 and drug containing it
NZ708990A (en) Method for activating helper t cell
RU2013126581A (en) STREPTokinase MUTANTS AND THEIR COVALENT MODIFIED FORMS
WO2014057484A8 (en) Peptides for the treatment of neurodegenerative diseases
WO2013096868A3 (en) Saposin-a derived peptides and uses thereof
WO2011156453A3 (en) Therapeutic peptides
MX2009004243A (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use.
WO2008040190A8 (en) Small peptides for anti-angiogenesis and use thereof
WO2008093058A3 (en) Peptides and their use
MX2019006515A (en) Compositions comprising peptide wkdeagkplvk.
WO2011112856A3 (en) Novel protein peptide hydrogels
EA201590601A1 (en) APPLICATION OF PEDF-DERIVED POLYPEPTIDES FOR THE TREATMENT OF OSTEOARTHRITIS
WO2009047513A3 (en) Antagonists of kisspeptin and uses thereof
EP4275751A3 (en) Improved naglu fusion protein formulation
EP2552462A4 (en) Ccn3 peptides and analogs thereof for therapeutic use
NZ711281A (en) Short bio-active peptides for promoting wound healing

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11740783

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11740783

Country of ref document: EP

Kind code of ref document: A2